MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Intra-Cellular Therapies Inc

Gesloten

SectorGezondheidszorg

131.89 -0.02

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

131.89

Max

131.89

Belangrijke statistieken

By Trading Economics

Inkomsten

9.4M

-17M

Verkoop

24M

199M

EPS

-0.16

Winstmarge

-8.475

Werknemers

860

EBITDA

9.8M

-29M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-0.79% downside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.8B

14B

Vorige openingsprijs

131.91

Vorige sluitingsprijs

131.89

Nieuwssentiment

By Acuity

51%

49%

320 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Intra-Cellular Therapies Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jan 2025, 12:11 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

13 jan 2025, 11:40 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

14 mrt 2025, 09:30 UTC

Top Nieuws

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

22 jan 2025, 14:09 UTC

Top Nieuws
Winsten

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 jan 2025, 11:22 UTC

Top Nieuws
Winsten

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

13 jan 2025, 21:20 UTC

Acquisities, Fusies, Overnames

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

13 jan 2025, 20:12 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

13 jan 2025, 16:18 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

13 jan 2025, 15:57 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

13 jan 2025, 14:10 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

13 jan 2025, 12:25 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 jan 2025, 11:57 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 jan 2025, 11:56 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

13 jan 2025, 11:45 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

13 jan 2025, 11:43 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

13 jan 2025, 11:43 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

13 jan 2025, 11:42 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

13 jan 2025, 11:41 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

13 jan 2025, 11:40 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

13 jan 2025, 11:34 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

13 jan 2025, 11:32 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

13 jan 2025, 11:32 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

13 jan 2025, 11:31 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

13 jan 2025, 11:31 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

13 jan 2025, 11:30 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

13 jan 2025, 10:55 UTC

Acquisities, Fusies, Overnames

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

13 jan 2025, 10:41 UTC

Acquisities, Fusies, Overnames

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

Peer Vergelijking

Prijswijziging

Intra-Cellular Therapies Inc Prognose

Koersdoel

By TipRanks

-0.79% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 130.83 USD  -0.79%

Hoogste 132 USD

Laagste 118 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Intra-Cellular Therapies Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

4

Buy

9

Hold

0

Sell

Technische score

By Trading Central

131.45 / 131.87Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

No Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

320 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.